MAR-CIPROFLOXACIN TABLET

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE)

Saatavilla:

MARCAN PHARMACEUTICALS INC

ATC-koodi:

J01MA02

INN (Kansainvälinen yleisnimi):

CIPROFLOXACIN

Annos:

500MG

Lääkemuoto:

TABLET

Koostumus:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 500MG

Antoreitti:

ORAL

Kpl paketissa:

10/50/1000

Prescription tyyppi:

Prescription

Terapeuttinen alue:

QUINOLONES

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0123207001; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2012-02-22

Valmisteyhteenveto

_MAR-CIPROFLOXACIN Page _
_1_
_ of _
_64_
_ _
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
MAR-CIPROFLOXACIN
Ciprofloxacin Tablets
Tablets, 250 mg, 500 mg and 750mg ciprofloxacin (as ciprofloxacin
hydrochloride), Oral
British Pharmacopoeia (BP)
Antibacterial Agent
Marcan Pharmaceuticals Inc.,
2 Gurdwara Road, Suite #112,
Ottawa, ON, K2E 1A2
Submission Control Number: 265922
Date of Initial Authorization:
FEB 22, 2021
Date of Revision:
JUL 22, 2022
_MAR-CIPROFLOXACIN Page _
_2_
_ of _
_64_
_ _
_ _
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
07/2022
4 DOSAGE AND ADMINISTRATION, 4.5 MISSED DOSE
07/2022
7 WARNINGS AND PRECAUTIONS
10/2020
TABLE OF CONTENTS
Sections or subsections that are not applicable at the time of
authorization are not listed.
RECENT MAJOR LABEL
CHANGES………………………………………………………………………………………………2
TABLE OF
CONTENTS…………………………………………………………………………………………………………………2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1. INDICATIONS
......................................................................................................................
4
1.1 Pediatrics
...............................................................................................................................
7
1.2 Geriatrics
...............................................................................................................................
7
2. CONTRAINDICATIONS
.........................................................................................................
7
3. SERIOUS WARNINGS AND PRECAUTIONS BOX
.....................................................................
8
4. DOSAGE AND ADMINISTRATION
.........................................................................................
8
4.1 Dosing
Considerations.............................................................